VILLA DURAZZO PALLAVICINI – FRIDAY 6 SEPTEMBER
17.30
Management of acquired Haemophilia A: A case series
S. Varvello (Italy)
VIEW ePOSTER
17.40
Immune Tolerance Induction with Nuwiq® (Simoctocog Alfa) in Nine Patients with Severe Haemophilia A and Inhibitors to FVIII
R.J. Liesner (UK)
VIEW ePOSTER
17.50
Final results from the NuProtect study of Nuwiq® (simoctocog alfa) treatment in previously untreated patients with severe haemophilia A
R.J. Liesner (UK)
VIEW ePOSTER
18.00
Combination of emicizumab with simoctocog alfa for prophylaxis in previously untreated/minimally treated hemophilia A patients, and for managing inhibitor patients
R. Sidonio (USA)
VIEW ePOSTER
18.10
Population pharmacokinetic model for recombinant factor VIII Fc fusion protein (rFVIIIFc) validated and optimized for use in children
L.H. Bukkems (The Netherlands)
VIEW ePOSTER
18.20
The combination of plasma-derived FVIII/VWF with emicizumab has non-additive effects on thrombin generation assay independently of the presence of inhibitors in hemophilia A plasma
A. Perez (Spain)
VIEW ePOSTER
VILLA DURAZZO PALLAVICINI – SATURDAY 7 SEPTEMBER
18.30
Prognostic value of polymorphisms of the CYP2C19 gene in the development of stent thrombosis
A. Zhunuspekova (Croatia)
VIEW ePOSTER
18.40
Six years of experience with plasma fractionation industries at a private super speciality hospital in South India: renaissance in usage of excess plasma in blood banks
B. Poluru Mranikrinda (India)
VIEW ePOSTER
18.50
Evaluation of the chromogenic assay “Biophen factor IX” on Sysmex CS-2400 analyzer
C. Novembrino (Italy)
VIEW ePOSTER
19.00
Testing clot growth and thrombin wave patterns in haemophilia patients
C. Kluft (The Netherlands)
VIEW ePOSTER
19.10
Overview of efficacy and safety of a plasma-derived human von Willebrand factor concentrate for perioperative management and delivery in patients with hereditary VWF deficiency, unresponsive to dDAVP
F. Bridey (France)
VIEW ePOSTER